Author Tatsukawa, Masashi| Takaki, Akinobu| Shiraha, Hidenori| Koike, Kazuko| Iwasaki, Yoshiaki| Kobashi, Haruhiko| Fujioka, Shin-Ichi| Sakaguchi, Kohsaku| Yamamoto, Kazuhide|
Published Date 2011-10-21
Publication Title BMC Cancer
Volume volume11
Content Type Journal Article
JaLCDOI 10.18926/AMO/32914
FullText URL fulltext.pdf
Author Miyake, Yasuhiro| Iwasaki, Yoshiaki| Ishikawa, Shin| Tatsukawa, Masashi| Nawa, Toru| Kato, Jun| Takaki, Akinobu| Kobashi, Haruhiko| Sakaguchi, Kohsaku| Shiratori, Yasushi|
Abstract We report herein a case with acute hepatitis due to hepatitis B virus genotype Ae, concurrent with amebic colitis. A 39-year-old homosexual Japanese man was admitted to our hospital with jaundice. Laboratory tests showed an elevation of transaminase and positivity for hepatitis B surface antigen and IgM-type antibody to hepatitis B core antigen. The hepatitis B virus genotype was determined to be Ae. Furthermore, a mud-like stool with blood and mucous had sometimes been noted during the past 3 years, and amebic colitis was shown by colonofi berscopy during hospitalization. The patient was diagnosed with acute hepatitis B, concurrent with amebic colitis, and was successfully treated with lamivudine and metronidazole. In Japanese patients with acute hepatitis B virus genotype A infection, homosexual activity tends to be high. Furthermore, in Japanese homosexual men, amebiasis has been increasing. Thus, in Japanese patients with acute hepatitis B, a determination of genotype should be performed in order to investigate the route of transmission of hepatitis B virus, and a search for amebiasis should be performed in patients with acute hepatitis due to hepatitis B virus genotype A. Furthermore, education of homosexual men regarding hepatitis B virus, hepatitis B virus vaccination, and amebiasis is urgently required.
Keywords hepatitis B virus genotype homosexual amebic colitis lamivudine
Amo Type Case Report
Published Date 2007-02
Publication Title Acta Medica Okayama
Volume volume61
Issue issue1
Publisher Okayama University Medical School
Start Page 35
End Page 39
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 17332840
Web of Science KeyUT 000244432400005
JaLCDOI 10.18926/AMO/32813
FullText URL fulltext.pdf
Author Sawayama, Tomoyuki| Sakaguchi, Kohsaku| Senoh, Tomonori| Ohta, Takeyuki| Nishimura, Mamoru| Takaki, Akinobu| Tsuji, Takao| Shiratori, Yasushi|
Abstract <p>In patients with hepatocellular carcinoma (HCC), natural killer (NK) cell activity decreases significantly, and the reduced activity may be associated with the progression of HCC. In this study we evaluated the effects of pulsing with interleukin (IL)-2 and/or IL-12 on the activation of freshly isolated peripheral blood lymphocytes (PBL) derived from patients with HCC. PBL obtained from 9 HCC patients, 4 liver cirrhosis patients, and 9 normal subjects were cultured in the presence of IL-2 and/or IL-12. After 24 h of incubation, the levels of interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha presented in the supernatants were determined by enzyme-linked immunosorbent assay (ELISA). The IFN-gamma and TNF-alpha production of PBL pulsed by a combination of IL-2 and IL-12 was significantly higher than those of PBL stimulated by either IL-2 or IL-12 alone. The mRNA encoding perforin, granzyme B, as well as IFN-gamma and TNF-alpha, were markedly enhanced in PBL stimulated with a combination of IL-12 and IL-2. The pulsing procedure of IL-12 in combination with IL-2 resulted in the increase of IFN-gamma and TNF-alpha, and the expression of perforin and granzyme B mRNA in PBL obtained from HCC patients, as well as in those obtained from normal subjects. These results indicate that adoptive immunotherapy based on PBL pulsed with a combination of IL-2 and IL-12 may be a promising adjunctive strategy for HCC treatment.</p>
Keywords hepatocellular carcinoma(HCC) interleukin(IL)-2 interleukin(IL)-12 interferon(IFN)-r granzyme B
Amo Type Article
Published Date 2003-12
Publication Title Acta Medica Okayama
Volume volume57
Issue issue6
Publisher Okayama University Medical School
Start Page 285
End Page 292
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 14726965
Web of Science KeyUT 000187556500003
JaLCDOI 10.18926/AMO/32674
FullText URL fulltext.pdf
Author Kawaguchi, Mitsuhiko| Koide, Norio| Sakaguchi, Kohsaku| Shinji, Toshiyuki| Tsuji, Takao|
Abstract We showed that the combination of epidermal growth factor (EGF) and insulin is an essential supplement to Williams' #E medium for the formation of floating multicellular spheroids in primary culture of rat hepatocytes. Isolated hepatocytes assembled to form floating multicellular spheroids within 96 h through transient assembly of monolayer islands within the initial 24 h in dishes coated with liver-derived proteoglycans. However, the assembly of multicellular spheroids was severely suppressed in the absence of either EGF or insulin. The reduction of spheroid assembly was correlated with decreased attachment and subsequent decreased formation of monolayer islands within 24 h. The minimum amounts of EGF and insulin required for the formation of floating spheroids were 1 ng/ml and 0.4 microgram/ml, respectively. These results suggest that the enhancement of hepatocyte attachment provided by the combination of EGF and insulin during the early phase of culture is required for the formation of floating spheroids.
Keywords multicellular spheroid epidermal growth factor insulin rat hepatocyte primary culture
Amo Type Article
Published Date 1992-06
Publication Title Acta Medica Okayama
Volume volume46
Issue issue3
Publisher Okayama University Medical School
Start Page 195
End Page 201
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 1502925
Web of Science KeyUT A1992JB50400008
JaLCDOI 10.18926/AMO/32001
FullText URL fulltext.pdf
Author Takenami, Tatsuo| Sakaguchi, Kohsaku| Nishimura, Mamoru| Miyake, Yasuhiro| Miyashita, Manabi| Terao, Masako| Fujiwara, Akiko| Tsuji, Takao|
Abstract <p>This study evaluated the effects of azathioprine in combination with low-dose prednisolone in the management of patients with intractable autoimmune hepatitis. Thirteen patients with intractable autoimmune hepatitis who had an incomplete or arrested response to conventional prednisolone therapy, or who relapsed during prednisolone maintenance therapy were additionally administered 50 or 100 mg/day of azathioprine in combination with prednisolone. This regimen reliably induced complete remission in 12 of 13 patients, and these 12 remained in remission during the follow-up period with maintenance therapy of 50 mg/day of azathioprine in combination with 5 mg/day of prednisolone. The findings of the current study indicate that the azathioprine and low-dose prednisolone combined therapy may offer a satisfactory alternative therapy for patients with intractable autoimmune hepatitis who have an incomplete or arrested response to conventional prednisolone therapy, or who relapse during prednisolone maintenance therapy.</p>
Keywords autoimmune hepatitis azathioprine prednisolone
Amo Type Article
Published Date 2001-12
Publication Title Acta Medica Okayama
Volume volume55
Issue issue6
Publisher Okayama University Medical School
Start Page 341
End Page 347
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 11779096
Web of Science KeyUT 000172838400004
JaLCDOI 10.18926/AMO/31969
FullText URL fulltext.pdf
Author Piao, Cheng-Yu| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Fujio, Kozo| Kaneyoshi, Toshihiko| Araki, Yasuyuki| Hashimoto, Kuniaki| Senoh, Tomonori| Terada, Ryo| Nishida, Tomohiro| Kobashi, Haruhiko| Sakaguchi, Kohsaku| Shiratori, Yasushi|
Abstract <p>Lamivudine is widely used to treat patients with hepatitis B. However, the outcomes in patients with hepatocellular carcinoma (HCC) treated with lamivudine have not been established. This study was conducted to evaluate the outcomes of lamivudine treatment for patients with HCC using an untreated, matched control group. Thirty patients with controlled HCC orally received lamivudine. As controls, 40 patients with HCC who were not treated with lamivudine and matched for clinical features were selected. The lamivudine-treated and untreated groups were compared with respect to changes in liver function, HCC recurrence, survival, and cause of death. In the lamivudine-treated group, there was significant improvement in the Child-Pugh score at 24 months after starting treatment, while no improvement was observed in the untreated group. There was no significant difference in the cumulative incidence of HCC recurrence and survival between the groups. However, there was a significant difference in the cumulative incidence of death due to liver failure (P= 0.043). A significant improvement in liver function was achieved by lamivudine treatment, even in patients with HCC. These results suggest that lamivudine treatment for patients with HCC may prevent death due to liver failure. Further prospective randomized studies using a larger number of patients are required.</p>
Keywords liver failure Child-Pughscore recurrence survival resistant mutant
Amo Type Article
Published Date 2005-10
Publication Title Acta Medica Okayama
Volume volume59
Issue issue5
Publisher Okayama University Medical School
Start Page 217
End Page 224
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 16286955
Web of Sience KeyUT 000232835600006
JaLCDOI 10.18926/AMO/31688
FullText URL fulltext.pdf
Author Mouri, Hirokazu| Sakaguchi, Kohsaku| Sawayama, Tomoyuki| Senoh, Tomonori| Ohta, Takeyuki| Nishimura, Mamoru| Fujiwara, Akiko| Terao, Masako| Shiratori, Yasushi| Tsuji, Takao|
Abstract <p>Transforming growth factor-beta1 (TGF-beta1) exerts potent immunosuppressive effects. In this study, we investigated the potential role of TGF-beta1 produced by hepatocellular carcinoma (HCC) cell lines in immunosuppression mechanisms. Using the Mv1Lu cell-growth inhibition assay and an enzyme-linked immunosorbent assay (ELISA), we detected optimal levels of TGF-beta1 in the culture supernatants conditioned by the HCC cell lines PLC/PRF/5, Hep3B, and HepG2. To determine the biological activity of TGF-beta1 in the supernatants, we examined the effects of the culture supernatants on the production of interferon (IFN)-gamma induced during the culture of peripheral blood mononuclear cells (PBMCs) stimulated with interleukin (IL)-12. IFN-gamma production of IL-12-stimulated PBMCs in the 1:1 dilution of the acid-activated conditioned medium of PLC/PRF/5, Hep3B, and HepG2 reduced to 14.7 +/- 0.8, 17.3 +/- 9.0, and 35.9 +/- 14.6%, respectively, compared with the value in the culture with control medium (complete culture medium). These results suggest that HCC cells producing TGF-beta1 may reduce the generation or activation of cytotoxic T lymphocytes (CTL) and natural killer (NK) cells, and thus could enhance their ability to escape immune-mediated surveillance.</p>
Keywords hepatocellular carcinoma immunosuppression transforming growth factor-?1 (TGF-?1) interleukin-12 interferon-? (IFN-?)
Amo Type Article
Published Date 2002-12
Publication Title Acta Medica Okayama
Volume volume56
Issue issue6
Publisher Okayama University Medical School
Start Page 309
End Page 315
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 12685860
Web of Science KeyUT 000179959000006
JaLCDOI 10.18926/AMO/31582
FullText URL fulltext.pdf
Author Kawamoto, Hirofumi| Sakaguchi, Kohsaku| Takaki, Akinobu| Ogawa, Shin| Tsuji, Takao|
Abstract We investigated autoimmunity, as assessed by hypergammaglobulinemia and the presence of autoantibodies including anti-nuclear antibodies (ANA) and anti-liver membrane antibodies (LMA), in 149 patients with chronic hepatitis C, 55 patients with chronic hepatitis B and 11 patients with autoimmune hepatitis. There was no significant difference in the incidence of these autoantibodies between chronic hepatitis C and chronic hepatitis B. Nine patients with chronic hepatitis C satisfied the serological criteria of autoimmune hepatitis (ANA positive and gammaglobulin or serum IgG greater than 2500 mg/dl), but none of the patients with chronic hepatitis B met the criteria. This suggests that autoimmunity is greater in chronic hepatitis C than in chronic hepatitis B. Of the 9 patients with chronic hepatitis C, all 4 patients tested for human leukocyte antigen (HLA) phenotype had HLA-DR4, which is known to be associated with autoimmune hepatitis in Japanese patients. We believe that hepatitis C virus (HCV) infection enhances the initiation and perpetuation of autoimmunity in susceptible individuals.
Keywords chronic hepatitis C autoimmune hepatitis anti-nuclear antibodyies anti-liver membrane antibodies HLA
Amo Type Article
Published Date 1993-10
Publication Title Acta Medica Okayama
Volume volume47
Issue issue5
Publisher Okayama University Medical School
Start Page 305
End Page 310
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders Copyright© Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 8273454
Web of Sience KeyUT A1993ME47100003
Related Url http://ousar.lib.okayama-u.ac.jp/metadata/2332
JaLCDOI 10.18926/AMO/31129
FullText URL fulltext.pdf
Author Takaki, Akinobu| Sakaguchi, Kohsaku| Ogawa, Shin| Kawamoto, Hirofumi| Tsuji, Takao|
Abstract We investigated the specificities and characteristics of anti-cytoskeleton antibodies in 13 anti-smooth muscle antibody (ASMA)-positive patients with chronic liver disease C (CLD-C), and compared them with those in 7 ASMA-positive patients with autoimmune hepatitis (AIH), and 6 ASMA-positive patients with chronic liver disease B (CLD-B). Anti-microfilaments (anti-MF) were found not only in 6/7 AIH patients (85.7%), but also in 8/13 CLD-C patients (61.5%) with a relatively high incidence, when compared with 1/6 CLD-B patients (16.7%), while, there was no significant difference in the incidence of anti-intermediate filaments (anti-IMF), especially anti-IMF IgM, among these patient groups. Among the patients with CLD-C, the mean levels of serum gammaglobulin and IgG in the anti-MF-positive patients were 2.46 +/- 1.03 g/dl and 3277 +/- 1089 mg/dl, respectively, which were higher than those in the anti-MF-negative patients (1.60 +/- 0.53 g/dl, 2245 +/- 610 mg/dl) and those in the patients with CLD-B (1.60 +/- 0.57 g/dl, 2192 +/- 339 mg/dl). Furthermore, 4 of the 8 anti-MF-positive patients with CLD-C satisfied the serological criteria for the diagnosis of AIH. These findings suggest that autoimmune mechanisms might be involved in the pathogenesis of anti-MF-positive CLD-C, and that anti-MF might be used as a marker.
Keywords chronic liver disease C autoimmune hepatitis anti-smooth muscle antibodies anti-cytoskeleton antibodies anti-microfilament antibodies
Amo Type Article
Published Date 1994-06
Publication Title Acta Medica Okayama
Volume volume48
Issue issue3
Publisher Okayama University Medical School
Start Page 143
End Page 149
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders Copyright© 1999 Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 7942072
Web of Science KeyUT A1994NV04300005
Related Url http://ousar.lib.okayama-u.ac.jp/metadata/3090
JaLCDOI 10.18926/AMO/30729
FullText URL fulltext.pdf
Author Ohta, Takeyuki| Sakaguchi, Kohsaku| Fujiwara, Akiko| Fujioka, Shin-ichi| Iwasaki, Yoshiaki| Makino, Yasuhiro| Araki, Yasuyuki| Shiratori, Yasushi|
Abstract <p>This study was conducted to develop a simple surrogate index comprised of routinely available laboratory tests to reflect the histological fibrosis stage. Clinical characteristics and laboratory data from 368 and 249 consecutive patients with chronic hepatitis C, a training cohort and a validation cohort, respectively, were retrospectively evaluated. Platelet (Plt) count and albumin (Alb) level contributed to the discrimination of the respective fibrosis stages. We derived the fi brosis index (FI), FI = 8.0-0.01 x Plt (10 multiply 3/microliter) - Alb (g/dl), from a multiple regression model. FI significantly correlated with the histological fibrosis stage in both the initial and validation cohort at p=0.691 and p=0.661, respectively (Spearman's rank correlation coefficient, p&#60;0.0001). The sensitivity and positive predictive value of FI at a cutoff value &#60; 2.10 for predicting fibrosis stage F0-1 were 66.8% and 78.8% in the initial cohort and 68.5% and 63.6% in the validation cohort, respectively. Corresponding values of FI at a cutoff value &#62;- 3.30 for the prediction of F4 were 67.7% and 75.0% in the initial cohort and 70.8% and 81.0% in the validation cohort. The fibrosis index comprised of platelet count and albumin level reflected the histological fibrosis stage in patients with chronic hepatitis C.</p>
Keywords albumin level chronic hepatitis C fi brosis index fi brosis stage platelet count
Amo Type Article
Published Date 2006-04
Publication Title Acta Medica Okayama
Volume volume60
Issue issue2
Publisher Okayama University Medical School
Start Page 77
End Page 84
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
File Version publisher
Refereed True
PubMed ID 16680183
Web of Science KeyUT 000237001900002